<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of rabies
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of rabies
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of rabies
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan C Jackson, MD, FRCPC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keri K Hall, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2200122250">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rabies remains an important disease because there are at least 60,000 human deaths every year worldwide, particularly in Asia and Africa where dog rabies is endemic [
         <a href="#rid1">
          1
         </a>
         ]. In geographic locations where human rabies is rare, the diagnosis may not be considered until relatively late in the clinical course. There is no known effective treatment for rabies.
        </p>
        <p>
         Although rabies is usually preventable after recognized exposures with post-exposure rabies prophylaxis (eg, wound cleansing and administration of
         <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">
          rabies vaccine
         </a>
         and
         <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">
          rabies immune globulin
         </a>
         ), the need for prophylaxis is not always recognized and may not be readily available in some areas. In addition, human rabies may present without a history of an animal exposure, usually because a bat bite was not recognized.
        </p>
        <p>
         This topic will address the approach to managing patients with suspected or confirmed rabies. The epidemiology, clinical manifestations, diagnosis, and prevention of rabies are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8322.html" rel="external">
          "Clinical manifestations and diagnosis of rabies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8303.html" rel="external">
          "Rabies immune globulin and vaccine"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">
          "Indications for post-exposure rabies prophylaxis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1863712866">
         <span class="h1">
          CHOOSING A TREATMENT APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with confirmed or suspected rabies, management options include a palliative or aggressive approach. As of January 2023, there have been 30 well-documented rabies survivors  (
         <a class="graphic graphic_table graphicRef113372" href="/z/d/graphic/113372.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2-28
         </a>
         ]; the most recent survivors were from India. None of these patients received timely administration of a full course of a recommended post-exposure rabies prophylaxis regimen, and only a minority received
         <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">
          rabies immune globulin
         </a>
         . These cases do not include patients who had atypical features of rabies without the development of rabies virus-neutralizing antibodies (since they were likely not cases of rabies) [
         <a href="#rid29">
          29,30
         </a>
         ] or reports that did not have sufficient documentation [
         <a href="#rid31">
          31-34
         </a>
         ].
        </p>
        <p>
         Many factors influence the therapeutic approach in patients with rabies, including prognostic factors  (
         <a class="graphic graphic_table graphicRef113371" href="/z/d/graphic/113371.html" rel="external">
          table 2
         </a>
         ) and the risks of treatment (see
         <a class="local">
          'Combination therapies'
         </a>
         below). Although the relative importance of each of these factors is uncertain, in general:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A palliative approach is typically pursued in patients who are unlikely to survive or who would not accept survival with severe neurological sequelae. Factors associated with a poor prognosis include older age, comorbid conditions, late disease, no history of rabies vaccination, and diagnostic testing that is positive for rabies virus antigen/RNA and negative for neutralizing anti-rabies virus antibodies. (See
         <a class="local">
          'Palliative approach'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consideration of an aggressive approach would be reasonable for patients who have an increased likelihood of survival and who would accept severe neurologic sequelae. Factors that may be associated with a more favorable disease course include young age, lack of comorbidities, receipt of one or more doses of
         <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">
          rabies vaccine
         </a>
         prior to the onset of symptoms or signs, clinical manifestations consistent with early disease, and diagnostic testing that is negative for rabies virus antigen/RNA and positive for neutralizing anti-rabies antibodies. (See
         <a class="local">
          'Aggressive approach'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3173059113">
         <span class="h1">
          PALLIATIVE APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once a decision has been made to take a palliative approach for the care of a patient with rabies, the focus should be on comfort care in a hospital with liberal use of sedatives and analgesics in order to alleviate suffering [
         <a href="#rid35">
          35
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A quiet private room is highly desirable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pharmacologic restraints are preferred whenever possible over physical restraints. Benzodiazepines such as
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         are useful for sedation and muscle relaxation and can be given intravenously, intramuscularly, or per rectum.
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          Lorazepam
         </a>
         and
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         are alternative benzodiazepines, and both can be given intravenously or subcutaneously.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          Haloperidol
         </a>
         , which can be administered subcutaneously or intramuscularly, can be used for a variety of clinical manifestations, including restlessness, agitation, hyperexcitability, delirium, hallucinations, and aggression [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For analgesia,
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         can be administered intravenously or subcutaneously, including a subcutaneous infusion using a syringe driver that avoids the need for multiple injections [
         <a href="#rid37">
          37
         </a>
         ]. Both
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         and
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         can also be given subcutaneously using this method, and also in two- or three-drug combinations (eg, morphine, haloperidol, and midazolam).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excessive salivary secretions can be treated with anticholinergics, including
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          scopolamine
         </a>
         and
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         . The sensation of thirst can be alleviated with ice chips in the mouth.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever can be treated with sponging and antipyretics, including
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         and/or
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         Although palliative care in a hospital is preferred, in some cultures, it may be important for the patient to leave the hospital and return home for privacy, to reduce hospital costs, and/or for religious rites to be performed before death [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H601073181">
         <span class="h1">
          AGGRESSIVE APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         On rare occasions, patients with rabies have survived after aggressive care in critical care units  (
         <a class="graphic graphic_table graphicRef113372" href="/z/d/graphic/113372.html" rel="external">
          table 1
         </a>
         ). An aggressive treatment approach involves a combination of supportive care and the off-label use of presently available therapies that, although unproven, may have benefit based upon our current understanding of the disease. An improved understanding of basic mechanisms underlying the pathogenesis of rabies may provide insights for the future development of novel therapies [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8322.html" rel="external">
          "Clinical manifestations and diagnosis of rabies", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4278492965">
         <span class="h2">
          Supportive care in a critical care unit
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive care in a critical care unit is essential for an aggressive approach [
         <a href="#rid40">
          40
         </a>
         ]. There are many potential complications of rabies, particularly cardiac and respiratory [
         <a href="#rid41">
          41,42
         </a>
         ], that can best be addressed by a team of specialists with broad expertise.
        </p>
        <p>
         It is very likely that supportive care in critical care units was the most important factor for all rabies survivors to date  (
         <a class="graphic graphic_table graphicRef113372" href="/z/d/graphic/113372.html" rel="external">
          table 1
         </a>
         ), including a 15-year-old girl in Wisconsin who did not receive
         <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">
          rabies vaccine
         </a>
         [
         <a href="#rid19">
          19
         </a>
         ]. Her therapy, subsequently dubbed the "Milwaukee protocol," also included therapeutic coma with benzodiazepines and
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         ,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , and antiviral therapy with
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         ; this approach has not proved to be efficacious beyond the provision of supportive care [
         <a href="#rid43">
          43
         </a>
         ]. Studies comparing the use of aggressive supportive care alone with aggressive supportive care plus combination of therapies are needed.
        </p>
        <p class="headingAnchor" id="H1245372966">
         <span class="h2">
          Combination therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no data to support a specific approach to treatment for patients with rabies. However, similar to the therapeutic approach to certain cancers, human immunodeficiency virus (HIV) infection and chronic hepatitis C virus infection, the use of a combination of therapies may have the best chance of success in treating rabies [
         <a href="#rid40">
          40
         </a>
         ]. This involves combining treatments in different therapeutic categories (eg, immunotherapy, antiviral therapy, and neuroprotective therapy) as described below.
        </p>
        <p class="headingAnchor" id="H930700961">
         <span class="h3">
          Immunotherapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunotherapy with either
         <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">
          rabies vaccine
         </a>
         or human
         <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">
          rabies immune globulin
         </a>
         is controversial [
         <a href="#rid40">
          40
         </a>
         ]. However, all but one patient who survived rabies infection had received one or more doses of rabies vaccine before the onset of symptoms (none received a full course of a recommended post-exposure prophylaxis regimen)  (
         <a class="graphic graphic_table graphicRef113372" href="/z/d/graphic/113372.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">
          Rabies vaccine
         </a>
         – It is reasonable to administer rabies vaccine if the patient has not received a complete course of post-exposure prophylaxis (see
         <a class="medical medical_review" href="/z/d/html/8303.html" rel="external">
          "Rabies immune globulin and vaccine"
         </a>
         ). Viral clearance in rabies is associated with the development of an immune response, and an important hallmark of this response is the presence of neutralizing anti-rabies virus antibodies in the serum and cerebrospinal fluid [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, it is unknown if it is advantageous to give
         <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">
          rabies vaccine
         </a>
         to a patient with rabies. Inactivated rabies vaccines do not elicit a cytotoxic T-cell response [
         <a href="#rid45">
          45
         </a>
         ], and therefore their value for viral clearance may be limited. No live attenuated rabies vaccines are licensed for use in humans.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Human
         </strong>
         <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">
          rabies immune globulin
         </a>
         <strong>
          (HRIG)
         </strong>
         – HRIG is not routinely administered to patients with rabies because immunoglobulins do not cross an intact blood-brain barrier, and therefore, it is unknown to what extent immunoglobulins would facilitate viral clearance [
         <a href="#rid40">
          40
         </a>
         ]. In animal models of rabies, there is limited entry of immune effector cells across the blood-brain barrier [
         <a href="#rid46">
          46
         </a>
         ]. In experimentally infected, symptomatic mice, intramuscular and intraventricular administration of human antirabies virus monoclonal antibodies have been associated with improved outcomes [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, the use of HRIG in conjunction with a strategy to enhance drug delivery into the central nervous system (CNS) (eg, osmotic agents or ultrasound waves) [
         <a href="#rid48">
          48,49
         </a>
         ] may be beneficial. The efficacy and safety of intrathecal administration of HRIG are unknown. (See
         <a class="local">
          'Drug delivery into the central nervous system'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2657480937">
         <span class="h3">
          Antiviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         An aggressive treatment approach includes the use of one or more antiviral agents with the goal of reducing viral spread to uninfected cells [
         <a href="#rid48">
          48
         </a>
         ]. Antiviral therapy is used despite the lack of evidence supporting the efficacy of any available agent. Since there are no data to suggest one agent over another, the approach to therapy is solely opinion based and is often influenced by which toxicities the provider and the patient (or the patient's family) are willing to accept.
        </p>
        <p>
         Three agents (interferon-alfa,
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         , and
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         ) have been used in the treatment of adults with rabies. These agents have been associated with neuropsychiatric, hematologic, gastrointestinal, and/or autoimmune complications. A fourth drug, favipiravir, has failed to show efficacy in animal models of rabies and is not approved for human use in most countries outside of the research setting.
        </p>
        <p>
         If interferon-alfa is used, it should be administered intrathecally (eg, with at least 300,000 international units/day) via a lumbar infusion or an intraventricular infusion (eg, with an Ommaya reservoir). CNS penetration may be limited with intravenous or intramuscular administration. Since there are concerns about CNS penetration of
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         , if used, it should also be administered intrathecally or with an agent to enhance CNS penetration, if possible. (See
         <a class="local">
          'Drug delivery into the central nervous system'
         </a>
         below.)
        </p>
        <p>
         Studies of specific antiviral agents include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interferon-alfa
         </strong>
         – Rabies virus triggers an immune response after entering the nervous system, which includes a type I interferon (interferon-alpha/beta) response that may help limit viral replication. Although early reports of combined intramuscular and intrathecal administration [
         <a href="#rid50">
          50
         </a>
         ] and combined intravenous and intrathecal administration [
         <a href="#rid51">
          51
         </a>
         ] did not show a beneficial effect on the progression of the clinical disease in humans with rabies, there is some antirabies virus activity of interferon in cell culture and animal models [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          Ribavirin
         </a>
         – Ribavirin is a broad-spectrum antiviral agent that is a purine analogue and RNA mutagen. Ribavirin has in vitro activity against rabies virus infection but no demonstrated efficacy in mouse models [
         <a href="#rid52">
          52,53
         </a>
         ]. Multiple attempts at therapy of human rabies with intravenous ribavirin, with or without intrathecal administration, were not successful [
         <a href="#rid51">
          51,54,55
         </a>
         ]. Because ribavirin is known to shift the immune response toward a Th1-type inflammatory response [
         <a href="#rid56">
          56
         </a>
         ], and because of the importance of a balanced Th1/Th2 immune response for the clearance of rabies virus infection, there are concerns that ribavirin could suppress antibody production essential for recovery from rabies [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          Amantadine
         </a>
         – Amantadine is a synthetic antiviral agent that can inhibit in vitro replication of certain viruses, including rabies virus [
         <a href="#rid57">
          57,58
         </a>
         ]. However, amantadine did not show efficacy when inoculated at daily intervals into the site of intramuscular inoculation of rabies virus in a mouse model [
         <a href="#rid52">
          52
         </a>
         ]. Hence, there is little evidence to indicate that amantadine will be a useful therapeutic agent for the treatment of human rabies despite its inclusion in the Milwaukee protocol [
         <a href="#rid19">
          19,43
         </a>
         ]. A more detailed discussion of the Milwaukee protocol is found elsewhere. (See
         <a class="local">
          'Supportive care in a critical care unit'
         </a>
         above and
         <a class="local">
          'Therapies to avoid'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Favipiravir
         </strong>
         – Favipiravar (T-705) is a broad-spectrum viral RNA polymerase inhibitor that has been approved only in Japan to treat cases of influenza unresponsive to conventional therapy and has shown promise in
         <em>
         </em>
         in vitro and in vivo studies in a variety of viral infections [
         <a href="#rid59">
          59
         </a>
         ]. Favipiravir activity against rabies virus has been shown in vitro and in mouse model studies for post-exposure rabies prophylaxis but not for the therapy of rabies [
         <a href="#rid60">
          60,61
         </a>
         ]. In one report, therapy with favipiravir failed in six patients with rabies, including three adults and three children [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H243307772">
         <span class="h3">
          Neuroprotective therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuroprotective therapies produce benefits by favorably influencing the underlying etiology or pathogenesis and forestalling onset of disease or clinical decline [
         <a href="#rid63">
          63
         </a>
         ]. The development of neuroprotective therapies for acute neurologic disorders remains in its infancy despite many published research studies.
        </p>
        <p>
         There are no known effective neuroprotective agents for use in rabies. However, therapeutic (induced) brain hypothermia (targeted temperature management), administered with either a cooling helmet or intranasal cooling, could be considered as a potential adjunctive therapy for rabies in order to slow progression of the disease, reduce neuronal injury, and provide time for the development of an immune response [
         <a href="#rid44">
          44
         </a>
         ]. Brain hypothermia is the only effective neuroprotective therapy demonstrated for acute brain injury in witnessed cardiac arrest [
         <a href="#rid64">
          64,65
         </a>
         ] and is used in clinical practice for this indication, although some evidence suggests further studies should be done to confirm efficacy [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         Early studies suggested that the noncompetitive
         <em>
          N
         </em>
         -methyl-D-aspartate (NMDA) receptor antagonist
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         might be a promising neuroprotective therapy for rabies [
         <a href="#rid67">
          67
         </a>
         ], but subsequent investigations performed in vitro and in a mouse model of rabies failed to show efficacy [
         <a href="#rid68">
          68
         </a>
         ]. In addition, ketamine was used in the Milwaukee protocol, which, after the initial case report, was not found to be successful [
         <a href="#rid43">
          43
         </a>
         ]. NMDA receptor antagonists have also been shown to lack efficacy in clinical trials of acute stroke and traumatic brain injury [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p>
         Therapeutic coma, which involves the administration of high-dose anesthetic agents in order to achieve maximal metabolic suppression and neuronal preservation, has also been used for neuroprotection. However, we suggest that therapeutic coma be avoided; the rationale for this is described below. (See
         <a class="local">
          'Therapeutic coma'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2496757423">
         <span class="h3">
          Therapies to avoid
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that therapies such as corticosteroids,
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         , therapeutic coma, and prophylaxis for cerebral vasospasm
         <strong>
          not
         </strong>
         be used for the treatment of rabies. The rationales are described below.
        </p>
        <p>
         Two of these strategies, therapeutic coma and prophylaxis for cerebral vasospasm, are included in the Milwaukee protocol, an aggressive approach to treatment that also includes the use of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         . This protocol was developed, at least in part, based upon a possible excitotoxic mechanism of neuronal injury in rabies virus infection. Although this protocol was used to treat one survivor in 2004 [
         <a href="#rid14">
          14,19
         </a>
         ], it was found to be ineffective for the treatment of at least 61 subsequent cases [
         <a href="#rid43">
          43,44,71
         </a>
         ]. In addition, there is a lack of supportive evidence for an excitotoxic mechanism of neuronal injury in rabies [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3748211544">
         <span class="h4">
          Corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Corticosteroids should not be used in the treatment of rabies. Immune-mediated injury is not thought to play a significant role in the pathogenesis of rabies [
         <a href="#rid39">
          39,45
         </a>
         ]. In addition, corticosteroids reduce entry of other agents into the brain and spinal cord [
         <a href="#rid40">
          40
         </a>
         ]. In mouse models of rabies infection, they shorten the incubation period and increase mortality [
         <a href="#rid72">
          72
         </a>
         ]. Corticosteroids may also have a negative effect on the immune response needed for viral clearance.
        </p>
        <p class="headingAnchor" id="H2220320970">
         <span class="h4">
          Minocycline
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          Minocycline
         </a>
         has broad spectrum antimicrobial activity with anti-inflammatory, anti-apoptotic, and antioxidant properties [
         <a href="#rid48">
          48
         </a>
         ]. However, the empiric use of minocycline is strongly discouraged because harmful effects were observed in rabies virus infection of neonatal mice [
         <a href="#rid73">
          73
         </a>
         ] and also in a variety of animal models of neurodegenerative diseases [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2736271342">
         <span class="h4">
          Therapeutic coma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic coma involves the administration of high-dose anesthetic agents in order to achieve maximal metabolic suppression and neuronal preservation; however, its use is not supported by a solid scientific rationale [
         <a href="#rid43">
          43
         </a>
         ]. In addition, repeated use of therapeutic coma as part of the Milwaukee protocol has not been successful [
         <a href="#rid43">
          43,44,71
         </a>
         ]. Given the potential adverse effects and complications of therapeutic coma (eg, vasopressor dependency, increased risk of infection, association with intensive care unit mortality and complications), this strategy should
         <strong>
          not
         </strong>
         be used for the management of rabies [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2950949931">
         <span class="h4">
          Prophylaxis of cerebral vasospasm
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prophylactic use of the calcium channel antagonist
         <a class="drug drug_general" data-topicid="9702" href="/z/d/drug information/9702.html" rel="external">
          nimodipine
         </a>
         , vitamin C,
         <a class="drug drug_general" data-topicid="9484" href="/z/d/drug information/9484.html" rel="external">
          sapropterin
         </a>
         supplementation, and L-arginine for cerebral vasospasm are not recommended [
         <a href="#rid43">
          43
         </a>
         ]. Although there have been occasional reports of cerebral vasospasm using transcranial doppler ultrasound in rabies patients [
         <a href="#rid75">
          75
         </a>
         ], the clinical relevance of these findings is uncertain since neuropathological reports do not support the occurrence of cerebral vasospasm in rabies [
         <a href="#rid76">
          76
         </a>
         ]. In addition, it is unlikely that vasospasm plays an important role in the pathogenesis of rabies encephalitis. If cerebral vasospasm is present, it should be treated by raising the mean arterial pressure, similar to the way it would be managed in the setting of aneurysmal subarachnoid hemorrhage [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3897837275">
         <span class="h2">
          Drug delivery into the central nervous system
         </span>
         <span class="headingEndMark">
          —
         </span>
         The blood-brain barrier, and the blood-spinal cord barrier [
         <a href="#rid78">
          78
         </a>
         ], are important barriers that affect entry of therapeutic agents into the CNS and also the trafficking of cells into the CNS [
         <a href="#rid79">
          79
         </a>
         ]. Various strategies have been taken to allow drugs to cross these barriers, including the use of a prodrug to improve entry into the CNS or by using nanoparticles, intranasal drug delivery, intraventricular administration, or disruption of the blood-brain barrier with either osmotic agents or ultrasound waves [
         <a href="#rid48">
          48,49
         </a>
         ]. Development of blood-brain barrier permeability enhancers may in the future improve the entry of drugs and rabies virus-specific antibodies and immune cells into the CNS.
        </p>
        <p class="headingAnchor" id="H4006599958">
         <span class="h1">
          INFECTION PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no documented cases of rabies virus infection being transmitted from a patient to a health care worker. However, given the theoretic risk, individuals caring for a patient with rabies should use strategies to reduce the risk transmission. Oral secretions are of particular concern because of the possibility that they may contain infectious rabies virus.
        </p>
        <p>
         Prevention strategies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection control precautions
         </strong>
         – Infection control precautions should be practiced by all visitors and health care workers caring for patients with suspected or confirmed rabies. Different institutions may vary in their approach, but at a minimum, consistent standard precautions should be utilized by family members and health care workers when caring for a patient with rabies to minimize the need for post-exposure prophylaxis [
         <a href="#rid80">
          80-84
         </a>
         ]. As an example, health care workers should wear gowns, masks, gloves, and eye/face protection when there is risk of aerosols and splashes (eg, intubation and suctioning).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Post-exposure prophylaxis
         </strong>
         – A percutaneous, mucous membrane, or nonintact skin exposure to a patient's body fluids (including salivary secretions) or tissues justify initiation of post-exposure rabies prophylaxis (wound cleansing and administration of
         <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">
          rabies vaccine
         </a>
         and
         <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">
          rabies immune globulin
         </a>
         ). Such exposures typically occur before the diagnosis of rabies is considered.
        </p>
        <p>
        </p>
        <p>
         More detailed discussions of infection control precautions and rabies post-exposure prophylaxis are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">
          "Infection prevention: Precautions for preventing transmission of infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">
          "Indications for post-exposure rabies prophylaxis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8303.html" rel="external">
          "Rabies immune globulin and vaccine"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H594833526">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113373.html" rel="external">
          "Society guideline links: Rabies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4279115900">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients or their family members. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/82947.html" rel="external">
          "Patient education: Rabies (The Basics)"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4024.html" rel="external">
          "Patient education: Rabies (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2411344449">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Importance of post-exposure prophylaxis
         </strong>
         – There is no known effective treatment for symptomatic rabies. However, the disease can be very effectively prevented after recognized exposures using recommended courses of post-exposure rabies prophylaxis. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">
          "Indications for post-exposure rabies prophylaxis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8303.html" rel="external">
          "Rabies immune globulin and vaccine", section on 'Post-exposure prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to management of symptomatic disease
         </strong>
         – When rabies is either strongly suspected or has already been confirmed with laboratory tests, a clinical decision needs to be made whether to embark on a palliative or aggressive management approach. Many factors should be considered in making this decision  (
         <a class="graphic graphic_table graphicRef113371" href="/z/d/graphic/113371.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Choosing a treatment approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Palliative therapy
         </strong>
         – Palliative therapy typically includes liberal administration of sedatives, major tranquilizers, and analgesics in a quiet environment. (See
         <a class="local">
          'Palliative approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Aggressive therapy
         </strong>
         – An aggressive approach involves supportive care and a combination of experimental immunotherapy, antiviral, and neuroprotective treatments, although none of these therapies are proven to be effective. (See
         <a class="local">
          'Aggressive approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapies to avoid
         </strong>
         – We suggest that certain therapies not be used for the treatment of rabies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). These include corticosteroids,
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         , therapeutic coma, and the use of agents to prevent cerebral vasospasm. (See
         <a class="local">
          'Aggressive approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection control
         </strong>
         – There are no documented cases of rabies virus infection being transmitted from a patient to a health care worker. However, given the potential risk, individuals caring for a patient with rabies should use consistent infection control precautions. In addition, they should receive post-exposure prophylaxis if there was a percutaneous, mucous membrane, or nonintact skin exposure to the patient’s body fluids or tissues. (See
         <a class="local">
          'Infection prevention'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hampson K, Coudeville L, Lembo T, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis 2015; 9:e0003709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hattwick MA, Weis TT, Stechschulte CJ, et al. Recovery from rabies. A case report. Ann Intern Med 1972; 76:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porras C, Barboza JJ, Fuenzalida E, et al. Recovery from rabies in man. Ann Intern Med 1976; 85:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CDC. Rabies in a laboratory worker--New York. MMWR Morb Mortal Wkly Rep 1977; 26:183.
          </a>
         </li>
         <li class="breakAll">
          Tillotson JR, Axelrod D, Lyman DO. Follow-up on rabies - New York. MMWR 1977; 26:249.
         </li>
         <li class="breakAll">
          Galvez S, Basque M, Contreras L, et al. Survivor of rabies encephalitis in Chile. Platform presentation at the XXIVth International Meeting on Research Advances and Rabies Control in the Americas in Toronto, Ontario, Canada on October 27, 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madhusudana SN, Nagaraj D, Uday M, et al. Partial recovery from rabies in a six-year-old girl. Int J Infect Dis 2002; 6:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           M N, V U, Rs M, et al. Unique clinical and imaging findings in a first ever documented PCR positive rabies survival patient: A case report. J Clin Virol 2015; 70:83.
          </a>
         </li>
         <li class="breakAll">
          Weyer J, Msimang-Dermaux V, Paweska JT, et al. A case of human survival of rabies, South Africa. South African Journal of Infectious Diseases 2016; 31:66.
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Souza A, Madhusudana SN. Survival from rabies encephalitis. J Neurol Sci 2014; 339:8.
          </a>
         </li>
         <li class="breakAll">
          Karahocagil MK, Akdeniz H, Aylan O, et al. Complete recovery from clinical rabies: case report. Turkiye Klinikleri J Med Sci 2013; 33:547.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez L, Fajardo R, Lopez E, et al. Partial recovery from rabies in a nine-year-old boy. Pediatr Infect Dis J 1994; 13:1154.
          </a>
         </li>
         <li class="breakAll">
          Thakur BS. 2nd rabies survivor in country at P'kula hospital. Hindustan Times 2014.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu WT, Willoughby RE Jr, Dhonau H, Mack KJ. Long-term follow-up after treatment of rabies by induction of coma. N Engl J Med 2007; 357:945.
          </a>
         </li>
         <li class="breakAll">
          Ministerio da Saude in Brazil. Rabies, human survival, bat - Brazil: (Pernambuco). ProMED-mail 2008; 20081114.3599.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karande S, Muranjan M, Mani RS, et al. Atypical rabies encephalitis in a six-year-old boy: clinical, radiological, and laboratory findings. Int J Infect Dis 2015; 36:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar KV, Ahmad FM, Dutta V. Pituitary cachexia after rabies encephalitis. Neurol India 2015; 63:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manoj S, Mukherjee A, Johri S, Kumar KV. Recovery from rabies, a universally fatal disease. Mil Med Res 2016; 3:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willoughby RE Jr, Tieves KS, Hoffman GM, et al. Survival after treatment of rabies with induction of coma. N Engl J Med 2005; 352:2508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao A, Pimpalwar Y, Mukherjee A, Yadu N. Serial brain MRI findings in a rare survivor of rabies encephalitis. Indian J Radiol Imaging 2017; 27:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damodar T, Mani RS, Prathyusha PV. Utility of rabies neutralizing antibody detection in cerebrospinal fluid and serum for ante-mortem diagnosis of human rabies. PLoS Negl Trop Dis 2019; 13:e0007128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mani RS, Damodar T, S D, et al. Case Reports: Survival from Rabies: Case Series from India. Am J Trop Med Hyg 2019; 100:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ledesma LA, Lemos ERS, Horta MA. Comparing clinical protocols for the treatment of human rabies: the Milwaukee protocol and the Brazilian protocol (Recife). Rev Soc Bras Med Trop 2020; 53:e20200352.
          </a>
         </li>
         <li class="breakAll">
          Governo do Estado do Amazonas, Secreataria de Estado de Saude. Noticias: Amazonas registra o segundo caso de sobrevivência por raiva humana no Brasil. http://saude.am.gov.br/visualizar-noticia.php?id=3048 (Accessed on December 16, 2020). (Accessed on January 05, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bokade CM, Gajimwar VS, Meshram RM, Wathore SB. Survival of Atypical Rabies Encephalitis. Ann Indian Acad Neurol 2019; 22:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goyal K, Bhagwat C, Suthar R, et al. Enigma of Rabies: Prolonged Survival in a Boy with Rabies Brachial Plexitis and Encephalomyelitis. Neurol India 2020; 68:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           John B, Kumar S, Kumar S, et al. Child survivor of rabies in India: a case report. Paediatr Int Child Health 2020; 40:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zarate AA, Sanchez M, Flores-Lovon K, et al. Pregnant woman from southern Peru with rabies infection who delivered a healthy baby. Trop Doct 2021; 51:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Presumptive abortive human rabies - Texas, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:185.
          </a>
         </li>
         <li class="breakAll">
          Wiedeman J, Plant J, Glaser C, et al. Recovery of a patient from clinical rabies - California, 2011. MMWR 2012; 61:61.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rawat AK, Rao SK. Survival of a rabies patient. Indian Pediatr 2011; 48:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apanga PA, Awoonor-Williams JK, Acheampong M, Adam MA. A Presumptive Case of Human Rabies: A Rare Survived Case in Rural Ghana. Front Public Health 2016; 4:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu A, Shah P, Shen P, et al. Temporal evolution on MRI of successful treatment of rabies. Clin Imaging 2015; 39:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sumirini AA, Manchanda BV, Mehra S. The Rare Case of a Human Rabies Survivor and the Comparative Study of All Documented Human Rabies Survivors Till 2021. J Neuroinfect Dis 2022; 13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warrell M, Warrell DA, Tarantola A. The Imperative of Palliation in the Management of Rabies Encephalomyelitis. Trop Med Infect Dis 2017; 2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsden SC, Cabanban CR. Rabies: A significant palliative care issue. Prog Palliat Care 2006; 14:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas T, Barclay S. Continuous subcutaneous infusion in palliative care: a review of current practice. Int J Palliat Nurs 2015; 21:60, 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarantola A, Crabol Y, Mahendra BJ, et al. Caring for patients with rabies in developing countries - the neglected importance of palliative care. Trop Med Int Health 2016; 21:564.
          </a>
         </li>
         <li class="breakAll">
          Jackson AC. Pathogenesis. In: Rabies: Scientific Basis of the Disease and its Management, 4, Fooks AR, Jackson AC (Eds), Elsevier Academic Press, London 2020. p.303.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson AC, Warrell MJ, Rupprecht CE, et al. Management of rabies in humans. Clin Infect Dis 2003; 36:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hattwick MA. Human rabies. Public Health Rev 1974; 3:229.
          </a>
         </li>
         <li class="breakAll">
          Jackson AC. Human disease. In: Rabies: Scientific Basis of the Disease and its Management, 4, Fooks AR, Jackson AC (Eds), Elsevier Academic Press, Oxford 2020. p.379.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiler FA, Jackson AC. Critical Appraisal of the Milwaukee Protocol for Rabies: This Failed Approach Should Be Abandoned. Can J Neurol Sci 2016; 43:44.
          </a>
         </li>
         <li class="breakAll">
          Jackson AC. Therapy of human rabies. In: Rabies: Scientific Basis of the Disease and its Management, 4, Fooks AR, Jackson AC (Eds), Elsevier Academic Press, London 2020. p.547.
         </li>
         <li class="breakAll">
          Lafon M. Immunology. In: Rabies: Scientific Basis of the Disease and its Management, 4, Fooks AR, Jackson AC (Eds), Elsevier Academic Press, London 2020. p.379.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy A, Phares TW, Koprowski H, Hooper DC. Failure to open the blood-brain barrier and deliver immune effectors to central nervous system tissues leads to the lethal outcome of silver-haired bat rabies virus infection. J Virol 2007; 81:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Melo GD, Sonthonnax F, Lepousez G, et al. A combination of two human monoclonal antibodies cures symptomatic rabies. EMBO Mol Med 2020; 12:e12628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appolinario CM, Jackson AC. Antiviral therapy for human rabies. Antivir Ther 2015; 20:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel MM, Patel BM. Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain. CNS Drugs 2017; 31:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merigan TC, Baer GM, Winkler WG, et al. Human leukocyte interferon administration to patients with symptomatic and suspected rabies. Ann Neurol 1984; 16:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warrell MJ, White NJ, Looareesuwan S, et al. Failure of interferon alfa and tribavirin in rabies encephalitis. BMJ 1989; 299:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bussereau F, Picard M, Blancou J, Sureau P. Treatment of rabies in mice and foxes with antiviral compounds. Acta Virol 1988; 32:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appolinario CM, Prehaud C, Allendorf SD, et al. Ribavirin has an in vitro antiviral effect in rabies virus infected neuronal cells but fails to provide benefit in experimental rabies in mice. J Virol Antivir Res 2013; 2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control (CDC). Human rabies--Texas. MMWR Morb Mortal Wkly Rep 1984; 33:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kureishi A, Xu LZ, Wu H, Stiver HG. Rabies in China: recommendations for control. Bull World Health Organ 1992; 70:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powers CN, Peavy DL, Knight V. Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob Agents Chemother 1982; 22:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bussereau F, Chermann JC, De Clercq E, Hannoun C. Search for compounds which have an inhibitory effect on rhabdovirus multiplication in vitro. Ann Inst Pasteur Virol 1983; 134E:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Superti F, Seganti L, Panà A, Orsi N. Effect of amantadine on rhabdovirus infection. Drugs Exp Clin Res 1985; 11:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009; 82:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada K, Noguchi K, Komeno T, et al. Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. J Infect Dis 2016; 213:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banyard AC, Mansfield KL, Wu G, et al. Re-evaluating the effect of Favipiravir treatment on rabies virus infection. Vaccine 2019; 37:4686.
          </a>
         </li>
         <li class="breakAll">
          Willoughby RE, Epstein CR. Favipiravir treatment of human rabies. Platform presentation at the XXXth International Meeting on Research Advances and Rabies Control in the Americas. Kansas City, Missouri October 2019.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoulson I. Experimental therapeutics of neurodegenerative disorders: unmet needs. Science 1998; 282:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002; 346:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little NE, Feldman EL. Therapeutic hypothermia after cardiac arrest without return of consciousness: skating on thin ice. JAMA Neurol 2014; 71:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockhart BP, Tsiang H, Ceccaldi PE, Guillemer S. Ketamine-mediated inhibition of rabies virus infection in vitro and in rat brain. Antivir Chem Chemother 1991; 2:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weli SC, Scott CA, Ward CA, Jackson AC. Rabies virus infection of primary neuronal cultures and adult mice: failure to demonstrate evidence of excitotoxicity. J Virol 2006; 80:10270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutherland BA, Minnerup J, Balami JS, et al. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke 2012; 7:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 2002; 1:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res 2013; 99:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enright JB, Franti CE, Frye FL, Behymer DE. The effects of corticosteroids on rabies in mice. Can J Microbiol 1970; 16:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson AC, Scott CA, Owen J, et al. Therapy with minocycline aggravates experimental rabies in mice. J Virol 2007; 81:6248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson AC. Is minocycline useful for therapy of acute viral encephalitis? Antiviral Res 2012; 95:242.
          </a>
         </li>
         <li class="breakAll">
          Willoughby RE, Roy-Burman A, Martin KW, et al. Generalised cranial artery spasm in human rabies. In: Towards the Elimination of Rabies in Eurasia, Dodet B, Fooks AR, Müller T, Tordo N (Eds), Basel, Kager 2008. p.367.
         </li>
         <li class="breakAll">
          Rossiter JP, Jackson AC. Pathology. In: Rabies: Scientific Basis of the Disease and its Management, 4, Fooks AR, Jackson AC (Eds), Elsevier Academic Press, London 2020. p.347.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diringer MN, Bleck TP, Claude Hemphill J 3rd, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care 2011; 15:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M. The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol 2011; 70:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bentivoglio M, Kristensson K. Tryps and trips: cell trafficking across the 100-year-old blood-brain barrier. Trends Neurosci 2014; 37:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon T, Marston D, Mallewa M, et al. Paralytic rabies after a two week holiday in India. BMJ 2005; 331:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber DJ, Rutala WA. Risks and prevention of nosocomial transmission of rare zoonotic diseases. Clin Infect Dis 2001; 32:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gongal G, Mudhusudana SM, Sudarshan MK, et al.. What is the risk of rabies transmission from patients. Asian Biomedicine 2012; 6:937.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. WHO Expert Consultation on Rabies, Third report. https://apps.who.int/iris/bitstream/handle/10665/272364/9789241210218-eng.pdf (Accessed on January 05, 2023).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Last updated May 2022. https://www.cdc.gov/infectioncontrol/pdf/guidelines/isolation-guidelines-H.pdf (Accessed on January 05, 2023).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16595 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25881058" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Estimating the global burden of endemic canine rabies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5063659" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Recovery from rabies. A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/180860" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Recovery from rabies in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Rabies in a laboratory worker--New York
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Rabies in a laboratory worker--New York
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Rabies in a laboratory worker--New York
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12118432" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Partial recovery from rabies in a six-year-old girl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26305826" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Unique clinical and imaging findings in a first ever documented PCR positive rabies survival patient: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26305826" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Unique clinical and imaging findings in a first ever documented PCR positive rabies survival patient: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24582283" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Survival from rabies encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24582283" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Survival from rabies encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7892092" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Partial recovery from rabies in a nine-year-old boy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7892092" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Partial recovery from rabies in a nine-year-old boy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17761604" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Long-term follow-up after treatment of rabies by induction of coma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17761604" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Long-term follow-up after treatment of rabies by induction of coma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25975650" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Atypical rabies encephalitis in a six-year-old boy: clinical, radiological, and laboratory findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25947994" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pituitary cachexia after rabies encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27429788" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Recovery from rabies, a universally fatal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15958806" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Survival after treatment of rabies with induction of coma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29089674" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Serial brain MRI findings in a rare survivor of rabies encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30695032" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Utility of rabies neutralizing antibody detection in cerebrospinal fluid and serum for ante-mortem diagnosis of human rabies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30398147" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Case Reports: Survival from Rabies: Case Series from India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33174958" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Comparing clinical protocols for the treatment of human rabies: the Milwaukee protocol and the Brazilian protocol (Recife).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33174958" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Comparing clinical protocols for the treatment of human rabies: the Milwaukee protocol and the Brazilian protocol (Recife).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31359946" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Survival of Atypical Rabies Encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32643686" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Enigma of Rabies: Prolonged Survival in a Boy with Rabies Brachial Plexitis and Encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32744918" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Child survivor of rabies in India: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33446075" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pregnant woman from southern Peru with rabies infection who delivered a healthy baby.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20186117" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Presumptive abortive human rabies - Texas, 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20186117" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Presumptive abortive human rabies - Texas, 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21813936" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Survival of a rabies patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27891499" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A Presumptive Case of Human Rabies: A Rare Survived Case in Rural Ghana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25956434" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Temporal evolution on MRI of successful treatment of rabies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The Rare Case of a Human Rabies Survivor and the Comparative Study of All Documented Human Rabies Survivors Till 2021
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30270909" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The Imperative of Palliation in the Management of Rabies Encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Rabies: A significant palliative care issue
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25715160" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Continuous subcutaneous infusion in palliative care: a review of current practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26806229" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Caring for patients with rabies in developing countries - the neglected importance of palliative care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26806229" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Caring for patients with rabies in developing countries - the neglected importance of palliative care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12491203" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Management of rabies in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Human rabies
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Human rabies
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26639059" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Critical Appraisal of the Milwaukee Protocol for Rabies: This Failed Approach Should Be Abandoned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26639059" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Critical Appraisal of the Milwaukee Protocol for Rabies: This Failed Approach Should Be Abandoned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26639059" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Critical Appraisal of the Milwaukee Protocol for Rabies: This Failed Approach Should Be Abandoned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17108029" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Failure to open the blood-brain barrier and deliver immune effectors to central nervous system tissues leads to the lethal outcome of silver-haired bat rabies virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32945125" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A combination of two human monoclonal antibodies cures symptomatic rabies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25156675" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Antiviral therapy for human rabies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28101766" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6205625" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Human leukocyte interferon administration to patients with symptomatic and suspected rabies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2510846" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Failure of interferon alfa and tribavirin in rabies encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2897770" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Treatment of rabies in mice and foxes with antiviral compounds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Ribavirin has an in vitro antiviral effect in rabies virus infected neuronal cells but fails to provide benefit in experimental rabies in mice
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6431252" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Human rabies--Texas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1394776" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Rabies in China: recommendations for control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6214993" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Selective inhibition of functional lymphocyte subpopulations by ribavirin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Search for compounds which have an inhibitory effect on rhabdovirus multiplication in vitro
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3013559" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Effect of amantadine on rhabdovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19428599" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26655300" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29132993" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Re-evaluating the effect of Favipiravir treatment on rabies virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29132993" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Re-evaluating the effect of Favipiravir treatment on rabies virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9804537" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Experimental therapeutics of neurodegenerative disorders: unmet needs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11856793" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11856794" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24798260" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Therapeutic hypothermia after cardiac arrest without return of consciousness: skating on thin ice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Ketamine-mediated inhibition of rabies virus infection in vitro and in rat brain
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17005706" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Rabies virus infection of primary neuronal cultures and adult mice: failure to demonstrate evidence of excitotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22394615" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Neuroprotection for ischaemic stroke: translation from the bench to the bedside.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12849400" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23369672" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Current and future approaches to the therapy of human rabies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4921874" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The effects of corticosteroids on rabies in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17409147" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Therapy with minocycline aggravates experimental rabies in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22728256" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Is minocycline useful for therapy of acute viral encephalitis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22728256" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Is minocycline useful for therapy of acute viral encephalitis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22728256" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Is minocycline useful for therapy of acute viral encephalitis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21773873" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21674586" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The blood-spinal cord barrier: morphology and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24780507" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Tryps and trips: cell trafficking across the 100-year-old blood-brain barrier.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16141158" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Paralytic rabies after a two week holiday in India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11170953" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Risks and prevention of nosocomial transmission of rare zoonotic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : What is the risk of rabies transmission from patients
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
